Bell
Bell Global Equities Fund
Global Large-cap
Dec 2024 → Apr 2026
Our archive holds 12 letters from this strategy, behind 17 investment theses and positions in 17 companies. Every quote below is copied verbatim from the letter it came from.
12 letters in 3 years — follow all of Bell for every strategy.
Its investment theses
- AstraZeneca PLCApr 2026AstraZeneca is a diversified biopharmaceutical compounder with a high-quality pipeline, durable growth, and attractive valuation.
- ASML Holding N.V.Apr 2026ASML is a semiconductor equipment leader with strong operating results, earnings upgrades, and a robust order book.
- HCA Healthcare, Inc.Apr 2026HCA Healthcare is a leading US hospital operator with scale advantages, strong free cash flow, and long-term earnings growth.
- Deutsche BoerseMar 2026Deutsche Boerse is a market infrastructure company with recurring revenues, structural growth drivers, and valuation upside.
- TE ConnectivityMar 2026TE Connectivity is a leading connector supplier with market share gains, double-digit growth potential, strong cash generation, and shareholder-friendly capital allocation.
- Nomura Research InstituteMar 2026Nomura Research Institute is a Japanese IT services and consultancy business with AI-driven growth and efficiency tailwinds.
- MercadoLibreMar 2026MercadoLibre is a founder-led Latin American e-commerce platform with strong scale, profitability, and long-term earnings growth potential.
- Abbott LaboratoriesJan 2026Abbott Laboratories is a diversified medtech leader with catalysts in Libre and PFA, enhanced oncology diagnostics, and an attractive entry after de-rating.
- SAP SEJan 2026SAP SE is a leading ERP provider with embedded software, attractive growth and valuation, and the capacity to adapt AI offerings despite near-term volatility.
- TeradyneSep 2025Teradyne is an attractive investment opportunity due to its strong market position in automated test equipment for advanced semiconductors and its growth potential in the robotics sector.